Is Viking Therapeutics Stock a Buy?
One of the current stars of the biotech world is Viking Therapeutics (NASDAQ: VKTX), and for good reason. The clinical-stage company is advancing to the later stages of developing a drug that, if approved, would compete in the white-hot market for weight loss medications.
While that's not the only product in the company's pipeline, it's the one that many investors have pinned their hopes on. Typically, for a biotech that's become popular, Viking's share price has hit a few peaks recently. Let's see if we can gauge if it's in for new ones.
That product is VK2735, an obesity treatment that has tested very well so far in the lab. In a phase 2 trial of an injectable form of the drug, it demonstrated body weight reduction from baseline after 13 weeks of use. It also demonstrated encouraging safety and tolerability.
Source Fool.com
Viking Therapeutics Inc Stock
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Viking Therapeutics Inc.
As a result the target price of 110 € shows a very positive potential of 96.29% compared to the current price of 56.04 € for Viking Therapeutics Inc.
